Meeting
2018 ASCO Annual Meeting
Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.
Authors
Yousef Zakharia
University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA
Yousef Zakharia , Olivier Rixe , John Harris Ward , Joseph J. Drabick , Montaser F. Shaheen , Mohammed M. Milhem , David Munn , Eugene Paul Kennedy , Nicholas N. Vahanian , Charles J. Link , Robert R. McWilliams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02073123
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9512)
DOI
10.1200/JCO.2018.36.15_suppl.9512
Abstract #
9512
Poster Bd #
339
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).
First Author: Daniel Olson
Poster
2016 ASCO Annual Meeting
Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.
First Author: Yousef Zakharia
Poster
2023 ASCO Annual Meeting
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.
First Author: Paolo Antonio Ascierto
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok